Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 801–900 of 1,015
Bolli, E., O’Rourke, J. P., Conti, L., Lanzardo, S., Rolih, V., Christen, J. M., Barutello, G., Forni, M., Pericle, F., & Cavallo, F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408746 · Cited by 72
Xu, Y., He, X., Wang, S., Sun, B., Jia, R., Chai, P., Li, F., Yang, Y., Ge, S., Jia, R., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02146-0 · Cited by 68
Fakhri, S., Moradi, S. Z., Yarmohammadi, A., Narimani, F., Wallace, C. E., & Bishayee, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834072 · Cited by 72
Chida, K., Kawazoe, A., Suzuki, T., Kawazu, M., Ueno, T., Takenouchi, K., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0041 · Cited by 70
“A preclinical study reported that theWnt/b-catenin pathway induced intrinsic resistance to ICIs in melanoma (11).”
BackgroundWang, H., Zhang, H., Chen, Y., Wang, H., Tian, Y., Yi, X., Shi, Q., Zhao, T., Zhang, B., Gao, T., et al. (2022) · Cells · doi:10.3390/cells11223580 · Cited by 73
“A previous report has revealed that the melanoma cell-intrinsic Wnt/β-catenin signaling activation is associated with the nonexistence of a T-cell gene expression signature, rendering the resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody treatment [46].”
BackgroundIGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?
Belfiore, A., Rapicavoli, R. V., Moli, R. L., Lappano, R., Morrione, A., Francesco, E. M. D., & Vella, V. (2023) · Biomedicines · doi:10.3390/biomedicines11010229 · Cited by 76
Yuzhalin, A. E., Lowery, F. J., Saito, Y., Yuan, X., Yao, J., Duan, Y., Ding, J., Acharya, S., Zhang, C., Fajardo, A., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01509-5 · Cited by 72
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 73
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Ott, P. A., & Wu, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1357 · Cited by 72
Peñarando, J., Aranda, E., & Rodríguez‐Ariza, A. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.003 · Cited by 69
Tripathi, R., Modur, V., Senovilla, L., Kroemer, G., & Komurov, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657374 · Cited by 68
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
Betella, I., Turbitt, W. J., Szul, T., Wu, B., Martínez, A., Katre, A. K., Wall, J., Norian, L. A., Birrer, M. J., & Arend, R. C. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.010 · Cited by 68
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 67
Self-citationShaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy
Chen, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102606 · Cited by 71
Yu, T., Liu, Z., Tao, Q., Xu, X., Li, X., Li, Y., Chen, M., Liu, R., Chen, D., Wu, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216824 · Cited by 73
TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers
Zaman, G. J. R., de Roos, J. A. D. M., Libouban, M. A. A., Prinsen, M. B. W., de Man, J., Buijsman, R. C., & Uitdehaag, J. C. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0342 · Cited by 65
Stakheev, D., Táborská, P., Strizova, Z. O., Podrazil, M., Bartůňková, J., & Smrž, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-41182-5 · Cited by 67
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 69
Piazza, G. A., Ward, A., Chen, X., Maxuitenko, Y. Y., Coley, A. B., Aboelella, N. S., Buchsbaum, D. J., Boyd, M. R., Keeton, A. B., & Zhou, G. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.008 · Cited by 72
“The ability of PDE10 inhibitors to suppress β-catenin activity in tumor cells [13,14,19,20] also has the potential to elicit productive antitumor immune responses, given that inhibition of oncogenic β-catenin can activate dendritic cells and promote T cell tumor infiltration [54,55].”
BackgroundWenthe, J., Naseri, S., Labani‐Motlagh, A., Enblad, G., Wikstrom, K. I., Eriksson, E., Loskog, A., & Lövgren, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02895-7 · Cited by 66
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 74
Cai, Y., Ji, W., Sun, C., Xu, R., Chen, X., Deng, Y., Pan, J., Yang, J., Zhu, H., & Mei, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704965 · Cited by 69
Bacterial inhibition of Fas-mediated killing promotes neuroinvasion and persistence
Maudet, C., Kheloufi, M., Levallois, S., Gaillard, J., Huang, L., Gaultier, C., Tsai, Y.-H., Disson, O., & Lecuit, M. (2022) · Nature · doi:10.1038/s41586-022-04505-7 · Cited by 67
WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer
Du, W., Menjivar, R. E., Donahue, K. L., Kadiyala, P., Velez-Delgado, A., Brown, K. L., Watkoske, H. R., He, X., Carpenter, E. S., Angeles, C. V., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220503 · Cited by 69
In the Wnt-er of life: Wnt signalling in melanoma and ageing
Kaur, A., Webster, M. R., & Weeraratna, A. T. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.332 · Cited by 66
“In a recent study, Spranger et al (2015) showed that, in contrast to that early work from the Wang and Rosenberg (1996), mutant-stabilised b-catenin caused exclusion of T cells from melanoma tumours and reduced the efficacy of checkpoint inhibitors.”
ResultGorbet, M.-J., & Ranjan, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107456 · Cited by 68
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
“TGFβ produced by tumor stromal cells helps establish the EMT program in cancer cells by driving the expression of key transcription factors ZEB, Twist, Snail and Slug [170–172] while contributing to T-cell exclusion [89].”
BackgroundToulmonde, M., Lucchesi, C., Verbeke, S., Crombé, A., Adam, J., Geneste, D., Chaire, V., Laroche‐Clary, A., Perret, R. E., Bertucci, F., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103131 · Cited by 68
Wang, Z., Zhao, T., Zhang, S., Wang, J., Chen, Y., Zhao, H., Yang, Y., Shi, S., Chen, Q., & Liu, K. (2021) · Biomarker Research · doi:10.1186/s40364-021-00323-7 · Cited by 65
“Wnt/beta-catenin signaling activation leads to the exclusion of T-cell and resistance to immune therapy with anti-PD-L1/anti-CTLA-4 monoclonal antibody in autochthonous mouse melanoma models [123].”
BackgroundSahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 72
Inactivation of ABL kinases suppresses non–small cell lung cancer metastasis
Gu, J., Rouse, C., Xu, X., Wang, J., Onaitis, M. W., & Pendergast, A. M. (2016) · JCI Insight · doi:10.1172/jci.insight.89647 · Cited by 74
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
Kitano, S., Nakayama, T., & Yamashita, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00270 · Cited by 70
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
Leivonen, S., Pollari, M., Brück, O. E., Pellinen, T. S., Autio, M. I., Karjalainen‐Lindsberg, M., Mannisto, S., Kellokumpu‐Lehtinen, P., Kallioniemi, O., Mustjoki, S. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200105 · Cited by 72
“For example, in melanoma and bladder cancer, the Wnt/β-catenin pathway has been shown to be causal in preventing T-cell activation and trafficking into the tumor microenvironment.(24,25) In addition, it would be interesting to examine the distribution of other cell lineages and their phenotypes, and determine whether…”
BackgroundCrumley, S. M., Kurnit, K. C., Hudgens, C. W., Fellman, B. M., Tetzlaff, M. T., & Broaddus, R. R. (2018) · Modern Pathology · doi:10.1038/s41379-018-0148-x · Cited by 79
“Activation of the Wnt/β-catenin pathway in melanoma is associated with local immune suppression [31].”
BackgroundShields, B. D., Koss, B. S., Taylor, E. M., Storey, A. J., West, K. L., Byrum, S. D., Mackintosh, S. G., Edmondson, R., Mahmoud, F. A., Shalin, S. C., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1722 · Cited by 68
“We hypothesized one potential effect of forced E-cadherin expression in the B16F10 line would be dampening of β-catenin signaling as active βcatenin signaling has been implicated in resistance to PD-1 checkpoint blockade (10).”
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 69
“1172/JCI140752 ized by the presence of immunosuppressive MDSCs and modest T cell infiltration (31, 54).”
BackgroundLymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas
Sasso, M. S., Mitrousis, N., Wang, Y., Briquez, P. S., Hauert, S., Ishihara, J., Hubbell, J. A., & Swartz, M. A. (2021) · Science Advances · doi:10.1126/sciadv.abe4362 · Cited by 66
“To validate these findings in a different mouse melanoma model, we generated VEGF-C–overexpressing and control variants from a tumor cell line derived from melanomas growing in BrafV600EPten−/− genetically modified mice [BP cell line (15)].”
MethodDeciphering the excited state behavior for 2-(4′-N,N-Dimethylaminophenyl)imidazo[4,5-b]pyridine
Zhao, J., Liu, X., & Zheng, Y. (2017) · Journal of Luminescence · doi:10.1016/j.jlumin.2017.03.056 · Cited by 62
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Ganesh, S., Koser, M. L., Cyr, W. A., Chopda, G. R., Tao, J., Shui, X., Ying, B., Chen, D., Pandya, P., Chipumuro, E., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0309 · Cited by 61
Yaguchi, T., & Kawakami, Y. (2016) · International Immunology · doi:10.1093/intimm/dxw030 · Cited by 66
Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries
Ho, P.-C., & Kaech, S. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.04.003 · Cited by 59
Linch, M. D., Goh, G., Hiley, C. T., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y. N. S., King, H., Furness, A. J. S., Freeman, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx355 · Cited by 66
“Wnt signalling and modulation of immune response Activation of tumour intrinsic Wnt/b-catenin signalling in melanoma has recently been reported to lead to T-cell exclusion from the tumour preventing anti-tumour immunity [23].”
BackgroundTK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Zizzari, I. G., Napoletano, C., Botticelli, A., Caponnetto, S., Calabrò, F., Gelibter, A. J., Rughetti, A., Ruscito, I., Rahimi, H., Rossi, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0594 · Cited by 64
“In melanoma, intrinsic activation of the Wnt/-catenin pathway correlates with absence of T cells in the microenvironment (42).”
BackgroundWang, Z., Zhao, J., Ma, Z., Cui, J., Shu, Y., Liu, Z., Cheng, Y., Leaw, S. J., Wu, Y., Ma, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.007 · Cited by 64
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer
Wise, D. R., Schneider, J. A., Armenia, J., Febles, V. A., McLaughlin, B. E., Brennan, R., Thoren, K. L., Abida, W. M., Sfanos, K. S., Marzo, A. M. D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00097 · Cited by 64
“Activated canonical Wnt signaling has been reported to mediate immunosuppression and resistance to checkpoint blockade in multiple cancer types.(24,29) DKK1 has been shown to promote tumor growth in preclinical models through modulation of NK cells and myeloid-derived suppressor cells.”
BackgroundXu, X. J., Li, J., Zou, J., Feng, X., Zhang, C., Zheng, R., Duanmu, W., Saha-Mandal, A., Ming, Z., & Wang, E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9292 · Cited by 67
Molecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 67
Plasmacytoid Dendritic Cells and Cancer Immunotherapy
Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2022) · Cells · doi:10.3390/cells11020222 · Cited by 65
IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma
Somani, V., Zhang, D., Dodhiawala, P. B., Lander, V. E., Liu, X., Kang, L., Chen, H.-P., Knolhoff, B. L., Li, L., Grierson, P. M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.02.035 · Cited by 73
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Mariniello, A., Borgeaud, M., WEINER, M. H., Frisone, D., Kim, F., & Addeo, A. (2025) · BioDrugs · doi:10.1007/s40259-024-00700-2 · Cited by 78
“In metastatic melanoma, WntT/β-catenin activation correlates with an immunosuppressive microenvironment [101], through the reduced tumor secretion of the cytokine CCL4, which normally promotes the recruitment and activation of immune cells.”
Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity
Yuan, H., Manoharan, I., Suryawanshi, A. S., Shanmugam, A., Swafford, D., Ahmad, S., Chinnadurai, R., Manicassamy, B., He, Y., Mellor, A. L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115941 · Cited by 61
“In addition to DC-intrinsic LRP5/6-signaling, active Wnt/b-catenin signaling within melanomas also promotes immune suppression.(32,33) Thus, our data indicates that signaling initiated by Wnts in the TME activates the b-catenin/TCF pathway in DCs, which suppresses host antitumor immune responses and promotes tumor gro…”
BackgroundRajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 57
“In addition, studies performing integrative analysis from publicly available TCGA data revealed a WNT/b-catenin signature associated with an absence of a T-cell expression signature (Spranger et al, 2015).”
BackgroundChrisikos, T. T., Zhou, Y., Slone, N., Babcock, R. L., Watowich, S. S., & Li, H. S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.01.014 · Cited by 65
“Moreover, β-catenin signaling in melanoma cells was found to prevent CCL4-dependent recruitment of DCs and generation of anti-tumor immunity (Spranger et al., 2015).”
BackgroundResultWnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity
Suryawanshi, A. S., Hussein, M. S., Prasad, P. D., & Manicassamy, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00122 · Cited by 64
“CD103 DCs play an important role in recruitment of CTLs in TME through their production of CXCL9 (C-X-C motif chemokine ligand 9) and CXCL10 (46, 47).”
BackgroundKudo, M. (2020) · Liver Cancer · doi:10.1159/000509554 · Cited by 65
Ballotti, R., Chéli, Y., & Bertolotto, C. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01290-7 · Cited by 67
Waaler, J., Mygland, L., Tveita, A. A., Strand, M. F., Solberg, N. T., Olsen, P. A., Aizenshtadt, A., Fauskanger, M., Lund, K., Brinch, S. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0916-2 · Cited by 63
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 70
“murine tumors that don’t express β-catenin responded to immune checkpoint therapy whilst tumors that present β-catenin levels did not respond [95].”
BackgroundTrajectory of immune evasion and cancer progression in hepatocellular carcinoma
Nguyen, P. H. D., Wasser, M., Tan, C. T., Lim, C. J., Lai, H. L. H., Seow, J. J. W., DasGupta, R., Phua, C. Z. J., Ma, S., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29122-w · Cited by 61
Peters, S., Paz-Ares, L. G., Herbst, R. S., & Reck, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004863 · Cited by 65
Liu, C., Shen, A., Song, J., Cheng, L., Zhang, M., Wang, Y., & Liu, X. (2023) · 癌症:英文版 · doi:10.1002/cac2.12507 · Cited by 66
“A total score ≥ 4 was considered as high expression to simplify data analysis [28, 29].”
BackgroundMultifunctional DDX3: dual roles in various cancer development and its related signaling pathways.
Zhao, L., Mao, Y., Zhou, J., Zhao, Y., Cao, Y., & Chen, X. '. (2016) · PubMed · Cited by 68
Pulluri, B., Kumar, A., Shaheen, M. F., Jeter, J., & Sundararajan, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.006 · Cited by 67
“A melanoma-intrinsic oncogenic pathway mediated by B catenin signaling activation, has shown to reduce intratumoral CD103+ DC numbers, thereby preventing tumor specific T-cell priming (37).”
BackgroundHamada, T., Soong, T. R., Masugi, Y., Kosumi, K., Nowak, J. A., da Silva, A., Mu, X. J., Twombly, T. S., Koh, H., Yang, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442999 · Cited by 69
“accumulation of CTNNB1 has been associated with more aggressive cancer behavior and suppression of anti-tumor immune response.(47,48) Its presence in a greater proportion of CD274/TIL TIME subtype could reflect potential muta-”
BackgroundImmuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
Song, M., Chen, X., Wang, L., & Zhang, Y. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.01 · Cited by 63
Matsuda, A., Ishiguro, K., Yan, I. K., & Patel, T. C. (2019) · Hepatology Communications · doi:10.1002/hep4.1311 · Cited by 60
20 years of histone lysine demethylases: From discovery to the clinic and beyond
Gray, Z. H., Honer, M. A., Ghatalia, P., Shi, Y., & Whetstine, J. R. (2025) · Cell · doi:10.1016/j.cell.2025.02.023 · Cited by 74
Bedognetti, D., Roelands, J. P., Decock, J. V., Wang, E., & Hendrickx, W. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170142 · Cited by 61
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
Yan, X., Zhang, S., Deng, Y., Wang, P., Hou, Q., & Xu, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01050 · Cited by 57
“Tumor-intrinsic activation of WNT/β-catenin signaling pathway results in subdued CCL4 expression and subsequent precluded dendritic cell (DC) recruitment and DC-mediated T-cell activities, thus leading to resistance to anti-PD-L1 and anti-CTLA-4 therapies (Spranger et al., 2015).”
BackgroundThe Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival
Santegoets, S. J. A. M., van Ham, V. J., Ehsan, I., Charoentong, P., Duurland, C. L., van Unen, V., Höllt, T., van der Velden, L., van Egmond, S. L., Kortekaas, K. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1749 · Cited by 61
Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 61
Bergholz, J. S., Wang, Q., Kabraji, S. K., & Zhao, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2300 · Cited by 61
“Of note, while BRAF/PTEN-null tumors responded to combined PD-L1/CTLA-4 blockade and exhibited significant growth inhibition, tumors with additional b-catenin activation failed to respond to this immunotherapy (24).”
BackgroundStemness in solid malignancies: coping with immune attack
Agudo, J., & Miao, Y. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00760-0 · Cited by 72
Shah, S., Ward, J. E., Bao, R., Hall, C. R., Brockstein, B. E., & Luke, J. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0087 · Cited by 58
Self-citationEmerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 61
Kolijn, K., Verhoef, E. I., Smid, M., Böttcher, R., Jenster, G. W., Debets, R., & van Leenders, G. J. L. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3752 · Cited by 60
Deng, W., Fernández, A., McLaughlin, S. L., & Klinke, D. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006122 · Cited by 62
“…/ /CAT-STA mice as melanoma models (13, 14), Damsky et al. (14) found that -catenin activation substantially increased melanoma lung metastasis, and Spranger et al. (15) revealed that melanoma-intrinsic active Wnt/ -catenin signaling prevented anti-tumor immunity via T-cell exclusion, thus…”
BackgroundMethodEnhancing KDM5A and TLR activity improves the response to immune checkpoint blockade
Wang, L., Gao, Y., Zhang, G., Li, D., Wang, Z., Zhang, J., Hermida, L. C., He, L., Wang, Z., Si, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2282 · Cited by 61
“Aberrant -catenin signaling inhibits the expression of the gene encoding CCL4, a chemokine that mediates trafficking of CD103+ DCs to tumors (50).”
BackgroundLiu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113618 · Cited by 59
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
Spain, L. A., Coulton, A., Lobón, I., Rowan, A., Schnidrig, D., Shepherd, S. T. C., Shum, B., Byrne, F., Goicoechea, M., Piperni, E., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1427 · Cited by 63
Wang, D., Wu, S., He, J., Sun, L., Zhu, H., Zhang, Y., Liu, S., Duan, X., Wang, Y., & Xu, T. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02758-2 · Cited by 62
“Blockade of β-catenin combined with immune checkpoint inhibitor has been demonstrated to promote complete tumor regression in homozygous mouse models of melanoma, breast cancer, neuroblastoma, and renal adenocarcinoma [41, 42].”
BackgroundWNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses
Mortezaee, K. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01274-z · Cited by 65
“Lack of T cell genomic signature and T cell infiltrate due to the intrinsic tumor-mediated WNT/β-catenin activity is contributed to the anti-PD-L1 resistance of melanoma [4].”
BackgroundTreatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 69
“Dysregulation of PTEN or aberrant activation of WNT–β-catenin signalling disrupt immune cell infiltration and antigen presentation, fostering an environment that favours immune escape 64,65 .”
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
“This activated pathway also results in failure of CD103C DC recruitment due to defective CCL4 chemokine production.(57) Failure of DCs to be recruited and migrate to lymph nodes prevents T cell activation and hence is one method that can lead to melanoma immune escape.”
BackgroundTherapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 60
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer
Wall, J., Klempner, S. J., & Arend, R. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1769065 · Cited by 58
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Shi, S., Gu, S. S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0778 · Cited by 60
“org Clin Cancer Res; 26(22) November 15, 2020 5991”
BackgroundInfluentialEmerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 65
“In a study of 266 cancer patients, responders to checkpoint blockade therapy more often had tumors harboring TILs (so-called ‘ hot ’ tumors), while non-responders had tumors with few TILs ( ‘ cold ’ tumors) (253).”
BackgroundStrategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 57
“Moreover, in melanoma animal models, this reduction in CCL4 impairs DC recruitment and resulting anti-tumor immunity (44).”
BackgroundJavitt, A., Shmueli, M. D., Kramer, M. P., Kolodziejczyk, A. A., Cohen, I., Radomir, L., Sheban, D., Kamer, I., Litchfield, K., Bab-Dinitz, E., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00557-4 · Cited by 59
Drug resistance mechanisms in cancers: Execution of pro-survival strategies
Dhanyamraju, P. K. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230248 · Cited by 70
Zhao, X., Ma, Y., Luo, J., Xu, K., Tian, P., Lu, C., & Song, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35989 · Cited by 66
“For example, β -catenin signaling in melanoma leads to T-cell rejection and resistance to anti-PD-L1 and anti-CTLA-4 monoclonal antibody therapy [208].”
BackgroundRNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy
Shi, J.-X., Zhang, Z., Yin, H.-Z., Piao, X.-J., Liu, C., Liu, Q.-J., Zhang, J.-C., Zhou, W.-X., Liu, F., Yang, F., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02132-6 · Cited by 63
“Recent advances respectively underscore the pivotal role of N6-methyladenosine (m6A) epigenetic modification in tumorigenesis [27], ferroptosis, and immune check-points [28–31].”
BackgroundDatar, I. J., & Schalper, K. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0336 · Cited by 56
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.